Evicenter
MarkdownMedical informationP&T meetings
Darovasertib (IDE196)

First-line metastatic uveal melanoma, in combination with crizotinib

Also known as LXS196
Manufacturer
IDEAYA Biosciences
Launch
Not announced
Last updated
206 sources

Section 3 of 6

Product information and disease description

403 evidence topics · 175 sources

Product description

Phase of product development

Launch

No evidence found.

FDA acceptance, priority review, and action date

No evidence found.

Origin at Novartis and the 2018 license to IDEAYA
Servier license for rights outside the United States, August 2025
Cash, cash runway, and financing
OptimUM-02 topline results expected in the first quarter of 2026, January to March 2026, superseded in April 2026

Product information

Generic, brand name and therapeutic class of product
Brand name of darovasertib

No evidence found.

Dosage forms and strengths
Investigational darovasertib tablet and crizotinib capsule in the OptimUM-02 trial
ProductPharmaceutical formRouteMaximum daily dose (mg)
Darovasertib“IDE196 (LXS196)”; “TABLET”“ORAL”“600”
Crizotinib“Crizotinib 200mg hard capsules”; “CAPSULE, HARD”“ORAL”“400”
Darovasertib tablet strengths and commercial formulation

No evidence found.

Average sales price and wholesale acquisition cost

Not applicable.

American hospital formulary service (AHFS), or other drug classification
AHFS and ATC classification of darovasertib

No evidence found.

Indication
Pharmacology
Mechanism of action
Rationale for combined PKC and MET inhibition: hepatocyte growth factor in the liver and MET overexpression
Pharmacodynamics
Pharmacokinetics
Darovasertib pharmacokinetics in combination with crizotinib

No evidence found.

Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
FDA-approved prescribing information for darovasertib

Not applicable.

Crizotinib label: hepatotoxicity, with liver function monitoring every 2 weeks for the first 2 months
Crizotinib label: QT interval prolongation, with ECG and electrolyte monitoring
Crizotinib label: bradycardia, with heart rate and blood pressure monitoring and review of bradycardic and antihypertensive medications

“Symptomatic bradycardia can occur in patients receiving XALKORI.” (opens the source at this quote in a new tab)

“Across clinical trials in patients with NSCLC, bradycardia occurred in 13% of 1719 patients treated with XALKORI.” (opens the source at this quote in a new tab)

“Grade 3 syncope occurred in 2.4% of XALKORI-treated patients and in 0.6% of the chemotherapy-treated patients” (opens the source at this quote in a new tab)

“Avoid using XALKORI in combination with other medications known to cause bradycardia (e.g., beta-blockers, nondihydropyridine-calcium channel blockers, clonidine, and digoxin) to the extent possible.” (opens the source at this quote in a new tab)

“Monitor heart rate and blood pressure regularly.” (opens the source at this quote in a new tab)

“If bradycardia occurs, re-evaluate for the use of concomitant medications known to cause bradycardia.” (opens the source at this quote in a new tab)

“Adult patients: Heart rate less than 60 beats per minute (bpm)” (opens the source at this quote in a new tab)

“Evaluate concomitant medications known to cause bradycardia, as well as antihypertensive medications.” (opens the source at this quote in a new tab)

“If contributing concomitant medication is identified and discontinued, or its dose is adjusted, resume at previous dose upon recovery to asymptomatic bradycardia or to the age-specific heart rate provided above.” (opens the source at this quote in a new tab)

“If no contributing concomitant medication is identified, or if contributing concomitant medications are not discontinued or dose adjusted, resume at reduced dose upon recovery to asymptomatic bradycardia or to the age-specific heart rate provided above.” (opens the source at this quote in a new tab)

Crizotinib label: severe visual loss and visual disorders, with monthly assessment of visual symptoms
Special populations
Crizotinib label: hepatic impairment, with dose reduction for moderate or severe impairment

“Reduce XALKORI dosage in patients with moderate or severe hepatic impairment” (opens the source at this quote in a new tab)

“No dose adjustment is recommended in patients with pre-existing mild hepatic impairment (AST > ULN and total bilirubin less than or equal to 1 times ULN or any AST and total bilirubin greater than 1 times ULN but less than or equal to1.5 times ULN).” (opens the source at this quote in a new tab)

“The recommended dose of XALKORI in patients with moderate hepatic impairment [any aspartate aminotransferase (AST) and total bilirubin greater than 1.5 times the upper limit of normal (ULN) and less than or equal to 3 times ULN] is the first dose reduction shown in Table 4 for adult patients with NSCLC or IMT” (opens the source at this quote in a new tab)

“The recommended dose of XALKORI in patients with severe hepatic impairment (any AST and total bilirubin greater than 3 times ULN) is the second dose reduction shown in Table 4 for adult patients with NSCLC or IMT” (opens the source at this quote in a new tab)

“Steady-state mean crizotinib AUC increased by 14% and Cmax increased by 9% in patients with moderate hepatic impairment (any AST and total bilirubin >1.5 times ULN and ≤3 times ULN) following XALKORI 200 mg orally twice daily compared with patients with normal hepatic function following XALKORI 250 mg orally twice daily.” (opens the source at this quote in a new tab)

“Mean crizotinib AUC decreased by 35% and Cmax decreased by 27% in patients with severe hepatic impairment (any AST and total bilirubin >3 times ULN) following XALKORI 250 mg orally once daily compared with patients with normal hepatic function following XALKORI 250 mg orally twice daily” (opens the source at this quote in a new tab)

Darovasertib pharmacokinetics in hepatic or renal impairment

No evidence found.

Drug/Drug, drug/disease interactions
Effects of other drugs on Darovasertib
Clinical drug interaction studies with darovasertib as the affected drug

No evidence found.

Crizotinib label: strong and moderate CYP3A inhibitors and grapefruit
Effects of Darovasertib on other drugs
Results of the pravastatin and drug interaction cocktail substudies

No evidence found.

Dosing and administration
Dosage
Crizotinib label: dose reduction levels for adults, with 200 mg twice daily as the first reduction
Dose reduction level for adult patients with NSCLC or IMTDose and schedule
First dose reduction“200 mg twice daily”
Second dose reduction“250 mg once daily”
Administration
Access and distribution
Specialty pharmacy distribution, pricing, and patient assistance

No evidence found.

Co-prescribed/Concomitant therapies
Antidiarrheal prophylaxis with the darovasertib and crizotinib combination

No evidence found.

Effect of Darovasertib on quality measures
Product-specific effects on healthcare quality measures

No evidence found.

Product comparison
Tebentafusp label: IMCgp100-202 efficacy results versus investigator’s choice
OutcomeKIMMTRAK (N=252)Investigator’s choice of pembrolizumab, ipilimumab, or dacarbazine (N=126)
Overall survival, number of deaths (%)“87 (34.5%)”“63 (50%)”
Overall survival, median in months (95% CI)“21.7 (18.6, 28.6)”“16 (9.7, 18.4)”
Progression-free survival, median in months (95% CI), final analysis“3.3 (3, 5)”“2.9 (2.8, 3)”
Objective response rate (95% CI), not formally tested“9.1% (5.9, 13.4)”“4.8% (1.8, 10.1)”
Complete response“1 (0.4%)”“0”
Partial response“22 (8.7%)”“6 (4.8%)”
Comparison, KIMMTRAK versus investigator’s choiceHazard ratio (95% CI)
Overall survival, prespecified interim analysis, stratified by LDH status“0.51 (0.37, 0.71)”
Progression-free survival, final analysis, stratified by LDH status“0.73 (0.58, 0.94)”
Melphalan hepatic delivery system label: boxed warning, general anesthesia, and REMS-certified settings

Place of product in therapy

Disease description

Definition and etiology
Epidemiology
Incidence of metastatic uveal melanoma
Annual number of new U.S. cases of metastatic uveal melanoma

No evidence found.

Prevalence of metastatic uveal melanoma
U.S. prevalence of uveal melanoma or of metastatic uveal melanoma

No evidence found.

Natural history, survival, and mortality
Estimated U.S. deaths in 2026, all eye and orbit cancer
Prognostic factors after metastasis: lactate dehydrogenase, alkaline phosphatase, and liver metastasis size
Pathophysiology
Diagnosis
Clinical presentation - signs and symptoms
Long-term morbidity
Hepatic and extrahepatic metastatic sites during follow-up
Burden of metastatic uveal melanoma
Humanistic burden and health-related quality of life
EORTC QLQ-C30 global health status and EQ-5D visual analogue scale in the IMCgp100-202 tebentafusp trial, intent-to-treat analysis set
EORTC QLQ-C30 global health status (score 0 to 100)Tebentafusp: participants assessedTebentafusp: meanTebentafusp: SDInvestigator's choice: participants assessedInvestigator's choice: meanInvestigator's choice: SD
Baseline (cycle 1)“173”“76.108”“20.233”“65”“74.872”“20.439”
Change from baseline at cycle 3“105”“0.952”“16.274”“35”“-0.238”“14.919”
Change from baseline at cycle 5“94”“-1.152”“20.797”“22”“-10.227”“22.557”
Change from baseline at cycle 9“57”“-2.193”“19.577”“13”“-8.333”“13.176”
Change from baseline at end of treatment“76”“-10.417”“20.911”“34”“-10.539”“23.148”
EQ-5D visual analogue scale (score 0 to 100)Tebentafusp: participants assessedTebentafusp: meanTebentafusp: SDInvestigator's choice: participants assessedInvestigator's choice: meanInvestigator's choice: SD
Baseline (cycle 1)“194”“81.0”“16.36”“78”“80.4”“18.31”
Change from baseline at cycle 3“136”“0.4”“14.69”“45”“-0.8”“14.28”
Change from baseline at cycle 5“108”“0.6”“15.61”“28”“-0.7”“14.38”
Change from baseline at cycle 9“71”“-0.9”“19.81”“14”“-3.3”“13.30”
Change from baseline at end of treatment“95”“-10.1”“22.53”“45”“-11.7”“21.40”
Economic burden and healthcare resource utilization
Healthcare costs by treatment type and adverse event-related costs in U.S. commercial and Medicare claims
Treatment group (Commercial and Medicare patients)Mean all-cause healthcare costs per patient per month (2025 US$)Mean adverse event-related costs per patient per month (2025 US$)Adverse event-related costs as a percentage of all-cause costs
All patients (n=423)“$28,859”“$2,607”“9.0%”
Chemotherapy (n=77)“$30,682”“$3,944”“12.9%”
Checkpoint inhibitors (n=145)“$36,056”“$4,158”“11.5%”
Tebentafusp (n=39)“$93,805”“$6,746”“7.2%”
Liver directed therapy (n=80)“$35,509”“$3,078”“8.7%”
Inpatient administration of tebentafusp during dose escalation in practice
Economic impact of metastatic uveal melanoma on families
Economic impact of diagnostic testing
Medicare coverage of gene expression profiling of the primary tumor

Approaches to treatment

Current treatment options and standard of care
Bispecific t-cell receptor therapy
Tebentafusp: IMCgp100-202 primary analysis of overall survival in the intention-to-treat population of 378 participants
Tebentafusp: IMCgp100-202 overall survival, progression-free survival, and response in the 3-year analysis

“In this 3-year analysis, the overall survival benefit continued to favor tebentafusp, with a stratified hazard ratio for death of 0.68 (95% CI, 0.54 to 0.87) (Fig. 1A). Median overall survival was 21.6 months (95% CI, 19.0 to 24.3) in the tebentafusp group and 16.9 months (95% CI, 12.9 to 19.5) in the control group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The percentage of patients who were surviving at 1, 2, and 3 years among those treated with tebentafusp was 72%, 45%, and 27%, respectively, as compared with 60%, 30%, and 18% among the patients in the control group (Fig. 1A and Table S4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Median progression-free survival was 3.4 months (95% CI, 3.0 to 5.4) in the tebentafusp group and 2.9 months (95% CI, 2.8 to 3.0) in the control group (stratified hazard ratio for progression or death, 0.76; 95% CI, 0.60 to 0.97) (Fig. 1B and Table S4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“With extended follow-up, the percentage of patients who had an objective response continued to be higher in the tebentafusp group than in the control group (11% vs. 5%), with five additional patients in the tebentafusp group having a partial response since the previous analysis (Table 1 and Fig. S5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Tebentafusp: IMCgp100-202 survival with progression on tebentafusp and treatment beyond radiographic progression at 5 years

“After adjusting for covariates, a post hoc analysis showed that patients who were treated with tebentafusp beyond radiographic progression had longer overall survival than those who discontinued treatment.” (opens the source at this quote in a new tab)

“Overall survival in patients with a best overall response of progressive disease by day 100 after randomization continued to be longer in the tebentafusp group than in the control group after a minimum duration of follow-up of 5-years [hazard ratio 0.61 (95% CI 0.43-0.88)” (opens the source at this quote in a new tab)

“Although the effect of TBP cannot be determined with certainty in this study, after adjusting for differences in these covariates, continued tebentafusp treatment was associated with improved postprogression survival [hazard ratio 0.61 (95% CI 0.44-0.83); Figure 5], with a similar trend of benefit among patients whose best overall response was progressive disease [hazard ratio 0.67 (95% CI 0.44-1.01)].” (opens the source at this quote in a new tab)

“Additionally, after rebaselining tumor burden at the point of initial disease progression, 27% (38/139) of tebentafusp patients treated beyond PD had subsequent tumor reduction compared with only 4% (1/28) of patients in the control group.” (opens the source at this quote in a new tab)

“Notably, 22% of patients in the control group received subsequent tebentafusp.” (opens the source at this quote in a new tab)

Cytokine release syndrome: management with antipyretics, fluids, and corticosteroids, and hospitalization in IMCgp100-202

“Unlike other trials of T-cell engagers, none of the three tebentafusp trials mandated any premedications as primary prophylaxis for CRS. The medications most frequently used to treat CRS were antipyretics (88%), intravenous fluids (45%), and systemic corticosteroids (25%; Table 3); four (1%) patients received tocilizumab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Most patients with CRS (64%) received only a single dose of systemic corticosteroid to manage their CRS episodes, and in a post hoc propensity score analysis of IMCgp100-202, early corticosteroid use to manage AE did not negatively affect OS when adjusted for baseline prognostic factors (Fig. 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In a retrospective analysis of hospitalizations, defined as either an extension of the mandated monitoring period during intra-patient dose escalation or an unplanned hospitalization at any time, in IMCgp100-202, a similar percentage of patients experienced an SAE-related hospitalization in the tebentafusp arm (24%) as in the investigator’s choice control arm (23%; Supplementary Table S8). In the tebentafusp group, most (65%) SAE-related hospitalizations occurred during the intra-patient dose-escalation period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Tebentafusp: CADTH recommendation, clinical findings, and inpatient monitoring for initial doses

“The CADTH pCODR Expert Review Committee (pERC) recommends that tebentafusp be reimbursed for the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM) in the first-line setting” (opens the source at this quote in a new tab)

“Tebentafusp was associated with a risk of cytokine release syndrome and dermatological adverse events. pERC acknowledged that while not insignificant, these adverse events are transient and manageable with monitoring in an inpatient setting for initial doses, supportive care, and dose adjustment.” (opens the source at this quote in a new tab)

“According to the clinical expert consulted by CADTH, the first 3 to 4 infusions of tebentafusp are associated with a risk of cytokine release syndrome which requires inpatient monitoring in an experienced institution and management by a specialist physician experienced in the use of tebentafusp. Subsequent infusions may be performed in community clinic setting.” (opens the source at this quote in a new tab)

“pERC discussed the indirect treatment comparison (ITC) submitted by the sponsor: an unanchored matching-adjusted indirect comparison (MAIC) of tebentafusp relative to ipilimumab plus nivolumab. pERC noted that while a statistically significant improvement in OS and progression-free survival (PFS) for tebentafusp was demonstrated, the results of the ITCs stem from highly uncertain evidence due to limitations that impact the internal and external validity, despite the various adjustments.” (opens the source at this quote in a new tab)

“The preparation of tebentafusp is complex and intense and will require considerable Pharmacy resources to prepare each dose.” (opens the source at this quote in a new tab)

Immune checkpoint inhibitors
First-line nivolumab plus ipilimumab: single-arm phase 2 trial of the Spanish Multidisciplinary Melanoma Group, 52 participants

“This was a single-arm, phase II trial led by the Spanish Multidisciplinary Melanoma Group (GEM) on nivo plus ipi for systemic treatment-naïve patients of age > 18 years, with histologically confirmed MUM, Eastern Cooperative Oncology Group-PS 0/1, and confirmed progressive metastatic disease (M1).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Nivo (1 mg/kg once every 3 weeks) and ipi (3 mg/kg once every 3 weeks) were administered during four inductions, followed by nivo (3 mg/kg once every 2 weeks) until progressive disease, toxicity, or withdrawal.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“A total of 52 patients with a median age of 59 years (range, 26-84 years) were enrolled.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The primary end point was 12-month OS, which was 51.9% (95% CI, 38.3 to 65.5).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The median OS and PFS were 12.7 months and 3.0 months, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Nivo plus ipi in the first-line setting for MUM showed a modest improvement in OS over historical benchmarks of chemotherapy, with a manageable toxicity profile.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Liver-directed therapies
Melphalan percutaneous hepatic perfusion: single-arm phase 3 FOCUS study, treated population of 91 participants

“The multicenter, open-label, phase 3 FOCUS study was designed to evaluate the efficacy and safety of melphalan/HDS in patients with unresectable mUM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Due to slow enrollment, with patient reluctance to receive BAC treatment, the study design was amended to a single-arm study, after which all eligible patients received treatment with melphalan/HDS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Eligible patients with mUM received treatment with melphalan (3.0 mg/kg ideal body weight) once every 6 to 8 weeks for a maximum of six cycles.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The study enrolled 102 patients with mUM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In the treated population ( n = 91), the ORR was 36.3 % (95 % confidence interval [CI], 26.44–47.01), including 7.7 % of patients with a complete response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The median DOR was 14 months, and the median OS was 20.5 months, with an OS of 80 % at 1 year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The median PFS was 9 months, with a PFS of 65 % at 6 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Melphalan percutaneous hepatic perfusion versus best alternative care: randomized portion of FOCUS, 85 participants

“The multicenter, open-label, Phase 3 FOCUS study was designed to evaluate the efficacy and safety of Melphalan/HDS in patients with unresectable mUM in comparison to best alternative care (BAC).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Due to slow enrollment and patient reluctance to receive BAC treatment, the study design was amended to a single-arm Melphalan/HDS study, and all efficacy analyses of the randomized study were treated as exploratory.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The study enrolled 85 patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Eligible patients were randomized to receive Melphalan/HDS ( n = 43) or BAC ( n = 42), and 72 patients received study treatment (Melphalan/HDS [ n = 40]; BAC [ n = 32]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Exploratory analyses of efficacy endpoints showed numerical differences consistently favoring the Melphalan/HDS arm versus BAC (median overall survival: 18.5 vs. 14.5 months; median progression-free survival: 9.1 vs. 3.3 months; objective response rate: 27.5% vs. 9.4%; and disease control rate: 80.0% vs. 46.9%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Serious adverse events (SAEs) occurred in 51.2% of Melphalan/HDS and in 21.9% of BAC patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Isolated hepatic perfusion versus best alternative care: randomized phase 3 trial, response and progression-free survival

“In this multicenter, randomized, open-label, phase III trial, patients with previously untreated isolated liver metastases from uveal melanoma were randomly assigned to receive a one-time treatment with IHP with melphalan or best alternative care (control group).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Patients with histologically or cytologically confirmed liver metastases from uveal melanoma were eligible if they had measurable disease according to RECIST version 1.1 criteria, had received no previous therapy for melanoma metastases (ie, first-line therapy), and had no evidence of extrahepatic disease by positron emission tomography-computed tomography (CT).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Ninety-three patients were randomly assigned, and 87 patients were assigned to either IHP (n = 43) or a control group receiving the investigator's choice of treatment (n = 44).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In an intention-to-treat analysis, the overall response rates (ORRs) were 40% versus 4.5% in the IHP and control groups, respectively ( P < .0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The median PFS was 7.4 months versus 3.3 months ( P < .0001), with a hazard ratio of 0.21 (95% CI, 0.12 to 0.36), and the median hPFS was 9.1 months versus 3.3 months ( P < .0001), both favoring the IHP arm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“There was one treatment-related death in the IHP group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Percutaneous hepatic perfusion with or without ipilimumab plus nivolumab: single-centre randomized phase 2 trial

“In this investigator-initiated, single-centre, open-label, randomised, phase 2 trial, adults aged 18-80 years with unresectable liver-only or liver-dominant metastatic uveal melanoma, WHO performance status 0-1, and with no previous systemic therapy were randomly assigned (1:1) to receive percutaneous hepatic perfusion alone (perfusion group) or percutaneous hepatic perfusion combined with ipilimumab plus nivolumab (combination group).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“1-year progression-free survival was 54·7% (95% CI 36·8-69·5) with combination therapy versus 15·8% (5·8-30·1) with perfusion alone (adjusted hazard ratio 0·34 [95% CI 0·19-0·60]; p=0·0002).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Grade 3-4 treatment-related adverse events occurred in 31 (82%) of 38 patients with combination therapy compared to 15 (41%) of 37 patients with perfusion alone, due to both a higher incidence of severe perfusion-related events and immunotherapy-related adverse events.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“One treatment-related death (due to triple M syndrome) occurred in the combination group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Hepatic arterial infusion, transarterial chemoembolization, and radioembolization: guideline summary
Cytotoxic chemotherapy
Temozolomide or dacarbazine as the control arm of a randomized phase 2 trial of selumetinib

“Randomized open-label phase II clinical trial comparing selumetinib versus chemotherapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“101 patients were randomized on a 1:1 ratio to selumetinib 75 mg orally twice daily on a continual basis (n=50) or chemotherapy (temozolomide 150 mg/m2 orally daily for 5 of every 28 days or DTIC 1000 mg/m2 intravenously every 21 days; investigator choice; n=51) until disease progression, death, intolerable toxicity, or withdrawal of consent.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Median progression-free survival for those randomized to chemotherapy and selumetinib was 7 (95% CI, 4.3 – 8.4; median treatment duration of 8 weeks (IQR, 4.3–16)) and 15.9 weeks (95% CI, 8.4 – 21.1; median treatment duration of 16.1 weeks (IQR, 8.1–25.3)), respectively (hazard ratio 0.46; 95% CI, 0.30 – 0.71; p < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Median overall survival was 9.1 (95% CI, 6.1 – 11.1) and 11.8 months (95% CI, 9.8 – 15.7) for those randomized to chemotherapy and selumetinib, respectively (hazard ratio 0.66; 95% CI, 0.41–1.06; p=0.09).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“No objective responses were observed with chemotherapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Temozolomide or dacarbazine versus cabozantinib: randomized phase 2 Alliance A091201 trial

“Alliance for Clinical Trials in Oncology A091201, a randomized phase II trial of the multiple TKI cabozantinib that also inhibits MET and VEGFR2 compared with temozolomide (TMZ) or dacarbazine (DTIC) in patients with metastatic UM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Patients with metastatic UM and RECIST measurable disease were randomized 2:1 to receive either cabozantinib (arm 1) versus temozolomide or dacarbazine (arm 2) with restaging imaging every two cycles.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Rates of PFS4 in arm 1 and arm 2 were 32.3% and 26.7% (p=0.35), respectively, with median PFS time of 60 and 59 days (p=0.964; HR=0.99).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Median overall survival was 6.4 months and 7.3 months (p=0.580; HR=1.21), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Grade 3–4 CTCAE adverse events were present in 61.3%, 46.7%, and 37.5% in arms 1, 2 and 2X, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“MET/VEGFR blockade with cabozantinib demonstrated no improvement in PFS but an increase in toxicity relative to temozolomide/dacarbazine in metastatic UM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Intravenous versus hepatic intra-arterial fotemustine: randomized phase 3 EORTC 18021 trial

“The prospective randomized phase III trial (EORTC 18021) thus aimed to compare the efficacy and safety of HIA versus IV fotemustine in UM patients with metastases in liver only.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Accrual was stopped after randomization of 171 patients based on the results of a futility OS analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“HIA did not improve OS (median 14.6 months) when compared with the IV arm (median 13.8 months), hazard ratio (HR) 1.09; 95% confidence interval (CI) 0.79–1.50, log-rank P = 0.59.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“However, there was a significant benefit on PFS for HIA compared with IV with a median of 4.5 versus 3.5 months, respectively (HR 0.62; 95% CI 0.45–0.84, log-rank P = 0.002).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“An improved RR was seen in the HIA (10.5%) compared with IV treatment (2.4%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The main grade ≥3 toxicity related to HIA was catheter complications (12%) and liver toxicity (4.5%) apart from two toxic deaths.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Targeted therapies and clinical trial enrollment
Selumetinib plus dacarbazine versus placebo plus dacarbazine: phase 3 SUMIT trial of 129 participants

“The Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) study was a phase III, double-blind trial” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“patients with metastatic uveal melanoma and no prior systemic therapy were randomly assigned (3:1) to selumetinib (75 mg twice daily) plus dacarbazine (1,000 mg/m2 intravenously on day 1 of every 21-day cycle) or placebo plus dacarbazine.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“A total of 129 patients were randomly assigned to receive selumetinib plus dacarbazine (n = 97) or placebo plus dacarbazine (n = 32).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“In the selumetinib plus dacarbazine group, 82 patients (85%) experienced a PFS event, compared with 24 (75%) in the placebo plus dacarbazine group (median, 2.8 v 1.8 months); the hazard ratio for PFS was 0.78 (95% CI, 0.48 to 1.27; two-sided P = .32).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“In patients with metastatic uveal melanoma, the combination of selumetinib plus dacarbazine had a tolerable safety profile but did not significantly improve PFS compared with placebo plus dacarbazine.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Limitations of current therapies
Summary: HLA restriction of tebentafusp and absence of approved therapy for HLA-A∗02:01-negative disease

Tebentafusp, the only FDA-approved systemic therapy for metastatic uveal melanoma, is approved by the FDA and the EMA as first-line systemic treatment for HLA-A∗02:01-positive patients, and only approximately 45% of individuals in the United States and Europe are HLA-A∗02:01-positive. HLA-A∗02:01-negative patients “continue to lack an established standard of care” and comprised 49% of individuals prescreened in the tebentafusp trial. There is no consensus on first-line systemic therapy for HLA-A∗02:01-negative patients; their current options are immune checkpoint inhibitors, “which are not specifically approved for mUM”, and participation in clinical trials, and the National Cancer Institute states that no effective method of systemic treatment has been identified for metastatic ocular melanoma. Within its eligible population, tebentafusp produced a 5-year overall survival rate of 16% versus 8% in the control group with an 11% overall response rate, almost all treated patients eventually progressed, and Piperno-Neumann et al. state that “a high unmet need remains”. Tebentafusp requires weekly intravenous administration with observation periods at initiation and inpatient monitoring for the first 3 to 4 infusions because of the risk of cytokine release syndrome, which occurred in 89% of tebentafusp-treated patients.

Summary: response, survival, and toxicity with immune checkpoint inhibitors

With PD-1 inhibitors in uveal melanoma, the objective response rate is below 5%, median progression-free survival 3 months, and 1-year overall survival approximately 50%. A meta-analysis reported a pooled objective response rate of 9.2% (4.1% for anti-CTLA4, 7.1% for anti-PD(L)1, and 13.5% for anti-CTLA4 plus anti-PD1) and a median overall survival of 11.5 months; a second meta-analysis of 1414 patients reported response rates of 3.4% with single-agent and 12.4% with dual checkpoint inhibition and median overall survival of 9.8 and 16.3 months. In two phase 2 trials of nivolumab plus ipilimumab, objective response rates were 11% and 18% and median overall survival 12 and 19 months. Pham et al. conclude that checkpoint inhibitors have limited efficacy in metastatic uveal melanoma. Dual checkpoint inhibition adds toxicity: in the 64 participants with metastatic uveal melanoma in CheckMate 401, 64% had grade 3-4 treatment-related adverse events and 30% discontinued; grade 3-4 treatment-related adverse events occurred in 40% of patients in one phase 2 trial and severe treatment-related adverse events in 39.1% of patients in a German series; 34 of 89 patients in a retrospective study across 14 academic medical centers discontinued for toxicity; and treatment-related discontinuation was 23% with nivolumab plus ipilimumab versus 2%-5% with pembrolizumab, without a clear survival advantage for the combination.

Summary: scope and risks of liver-directed therapy

Liver-directed therapy treats liver metastases alone: percutaneous hepatic perfusion “does not address extrahepatic disease”. Most patients have multifocal and small liver metastases, and around 10% are eligible for local therapy, with perioperative mortality and morbidity after surgery of approximately 2% and 14%. The FOCUS study of melphalan percutaneous hepatic perfusion enrolled patients with liver tumor involvement of up to 50% and excluded those with moderate or severe cirrhosis, portal hypertension, or NYHA II-IV status; grade 3 and 4 treatment-emergent adverse events occurred in 81.1% of patients, including thrombocytopenia in 54.7%, and 17.9% discontinued treatment because of them. In an earlier randomized trial, four deaths were attributed to melphalan percutaneous hepatic perfusion, and median overall survival did not differ significantly between arms (10.6 versus 10.0 months). Isolated hepatic perfusion is non-repeatable and carries higher morbidity and mortality, and in the SCANDIUM trial the primary endpoint was not met (24-month overall survival 46.5% versus 29.5%, P=0.12). Adding ipilimumab plus nivolumab to percutaneous hepatic perfusion raised grade 3-4 treatment-related adverse events from 41% to 82%.

Summary: outcomes with chemotherapy and earlier targeted therapies

Response rates to chemotherapy are below 10% regardless of the cytotoxic agent, with no demonstrated overall survival benefit over best supportive care. Across 40 studies, complete or partial remissions occurred in 39 of 841 patients (4.6%), with no responses in 22 of the 40 studies. In randomized trials, no objective responses were observed with temozolomide or dacarbazine and median overall survival was 9.1 months, the objective response rate with placebo plus dacarbazine was 0%, and median overall survival with temozolomide or dacarbazine was 7.3 months in another trial. In a literature review, systemic treatment was associated with response rates below 10%, median progression-free survival of 1.8-7.2 months, and median overall survival of 5.2-19.0 months, and pooled survival fell from 52% at 1 year to 25% at 2 years and 13% at 3 years. Among earlier targeted agents, selumetinib plus dacarbazine did not significantly improve progression-free survival over placebo plus dacarbazine, the response rate to MEK inhibitors averaged 2.5% (range 0 to 14%), and 3% of 153 participants achieved a partial response with the protein kinase C inhibitor AEB071. A standard of care has not been defined despite numerous phase 2 studies.

Place in treatment, anticipated use, and care setting
Summary: target population

The FDA has agreed to review the new drug application for darovasertib in combination with crizotinib for patients with first-line HLA-A∗02:01-negative metastatic uveal melanoma under the Real-Time Oncology Review program, and the submission includes data from OptimUM-02 and OptimUM-01. OptimUM-02 enrolled adults 18 years and older with histologically or cytologically confirmed metastatic uveal melanoma that is HLA-A∗02:01 negative, no prior systemic therapy in the metastatic or advanced setting and no prior regional or liver-directed therapy (ablation or resection of oligometastatic disease and neoadjuvant or adjuvant therapy were allowed), measurable disease per RECIST 1.1, ECOG performance status 0 or 1, and a life expectancy of at least 3 months. Participants could be initially diagnosed with metastatic disease or have metastases after therapy for localized uveal melanoma. The trial excluded prior treatment with a PKC inhibitor or an inhibitor directly targeting MET, symptomatic or untreated CNS metastases, a high risk of syncope or falls, stroke within the last 6 months, and clinically significant cardiac disease. OptimUM-01 data, including the phase 2 expansion in 101 HLA-A∗02:01-positive participants, are intended to support discussions on expanding the labeled indication. Crizotinib is FDA approved for ALK- or ROS1-positive metastatic non-small cell lung cancer, ALK-positive anaplastic large cell lymphoma, and ALK-positive inflammatory myofibroblastic tumor. Identifying the population requires HLA-A∗02:01 typing, which a reference laboratory reports in 3 to 7 days; in a deidentified database of 219 patients, HLA-A∗02:01 status was negative in 42.9% and unknown in 15.1%.

Summary: position relative to current first-line therapy by HLA status and disease distribution

For HLA-A∗02:01-positive patients, tebentafusp is approved by the FDA and the EMA as first-line systemic treatment and is recommended as standard of care in the first-line metastatic setting unless liver-directed treatment is required first for tumour debulking. For HLA-A∗02:01-negative patients, in the absence of a standard of care, liver-directed therapies (PHP and IHP), anti-PD-1-based immunotherapies, and clinical trial enrolment are the preferred options; patients with extensive disease are encouraged to enter a clinical trial, with percutaneous hepatic perfusion or checkpoint inhibitors alone or in combination as alternatives, and local therapies are proposed for limited hepatic metastases. By disease distribution, oligometastatic disease confined to the liver can be considered for resection or thermal ablation, and multifocal metastases confined to the liver for regional perfusion.

Darovasertib plus crizotinib would enter first-line treatment of HLA-A∗02:01-negative disease. In 313 participants of the phase 2b/3 portion of OptimUM-02, the combination reduced the risk of progression by blinded independent central review by 58% (hazard ratio 0.42; 95% CI 0.30 to 0.59) compared with investigator's choice of pembrolizumab, ipilimumab plus nivolumab, or dacarbazine, with median progression-free survival of 6.9 versus 3.1 months. Dr. Lutzky stated that tebentafusp remains the preferred first-line therapy for HLA-A∗02:01-positive disease, that darovasertib plus crizotinib may become an alternative for selected patients with rapidly progressive disease, extensive liver involvement, or a need for prompt tumor shrinkage, and the same report states that darovasertib plus crizotinib “appears likely to become the preferred systemic first-line option”; percutaneous hepatic perfusion remains important for liver-dominant disease with preserved hepatic function. Faculty in an OncLive report did not support combining darovasertib plus crizotinib with tebentafusp upfront because of overlapping toxicity, or frontline dual checkpoint inhibition outside a clinical trial. The ESMO 2026 poster authors describe the combination as a potential “new oral standard of care” in this setting, and IDEAYA cites OptimUM-01 in support of its potential for patients irrespective of HLA-A∗02:01 status and line of therapy. The progression-free survival data may enable an accelerated approval filing, with overall survival from a prespecified interim analysis expected in mid-2027 to support full approval.

Summary: anticipated use and care setting

The combination is taken orally: participants received darovasertib 300 mg twice daily plus crizotinib 200 mg twice daily, the recommended phase 2 dose, whereas the crizotinib label recommends 250 mg twice daily for NSCLC and lists 200 mg twice daily as its first dose reduction; crizotinib capsules are taken with or without food. The sponsor states that “A daily oral targeted regimen has the potential to improve compliance”. Tebentafusp, by comparison, requires weekly intravenous administration with observation at initiation, inpatient monitoring for the first 3 to 4 infusions in an experienced institution before subsequent infusions in a community clinic, and considerable pharmacy resources to prepare each dose.

Expert panelists noted that an oral regimen “removes the referral-forcing function that intravenous therapies create”, while the combination carries nausea, vomiting, diarrhea, and edema that low-volume community centers may not be able to manage; one panelist proposed a mandatory link to an expert center with community physicians managing maintenance. The short half-life of the combination typically makes brief holds and dose reductions, with dietary counseling, sufficient to keep patients on therapy, and the mean delivered dose intensity was 80% or more. Supportive measures for orthostatic hypotension during initial dosing include adequate hydration, initial withholding of blood pressure medications, and avoiding abrupt posture changes. The crizotinib label calls for liver function tests every 2 weeks during the first 2 months and then monthly, and ECG and electrolyte monitoring in patients with congestive heart failure, bradyarrhythmias, electrolyte abnormalities, or QT-prolonging medications; OptimUM-02 excluded strong CYP3A4/5 inducers or inhibitors and narrow therapeutic index CYP3A4/5 substrates. A 2026 guideline recommends discussing therapeutic options at an oncology or molecular tumour board in reference centres with expertise in uveal melanoma, and a community oncology practice reports treating metastatic uveal melanoma in most of its clinic locations, a disease a general oncologist may see only once every several years. Darovasertib is currently available only through clinical trials; IDEAYA has initiated planning for potential commercial operations and expects a moderately sized specialty sales force to reach the relevant specialists, and Servier will be responsible for commercialization outside the U.S.

Heterogeneity of treatment effect
Immune checkpoint inhibitors: MBD4-deficient hypermutated tumors
Care management intervention strategies
Other product development or post-marketing obligations required by the FDA

Not applicable.

Ongoing post-approval monitoring

Not applicable.

Expected outcomes of therapy